News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix presents part 1 data from JNJ-1900 (NBTXR3) in lung cancer at ESTRO 2026, showing promising responses. JNJ-1900 is a novel oncology product activated by radiotherapy -